Bezinga: Psychedelic companies keenly aware of creating therapies as healthcare reimbursement possibility looms

Pretty groundbreaking news here at Novamind! Recently Blue Cross Blue Shield agreed to cover intravenous ketamine for depression, despite still being off-label. This sets an exciting precedent going forward because it sends a strong signal that payors are interested in more effective treatments for mental health conditions as supporting research emerges. Feel free to check out the full article at the link below.